This article examines the use of classical as well as novel immunological agents to augment the immune system. Strategies to prevent infectious disease using vaccines to prime the immune system are discussed. A prospective overview of acquired immunodeficiency syndrome (AIDS) vaccine development provides insights into the possible agents that may be developed in the near future. The rationale for the use of intravenous immunoglobulin and colony stimulating factors in selected clinical situations is also discussed.
Get full access to this article
View all access options for this article.
References
1.
Delamarter JF : Hemopoietic colony stimulating factors: A physiological and pharmacological role in fighting infections. Biochem Pharmacol37:3057-3062, 1988
Herrmann F., Mertelsmann R.: Polypeptide controlling hematopoietic cell development and activation . Blut58:117-128,1989
4.
Ada GL: The traditional vaccines: An overview, in Woodrow GC, Levine MM (eds). New Generation Vaccines. New York, NY, Dekker, 1990, pp 19-30
5.
Fields BN, Chanock RM: What biotechnology has to offer vaccine development. Rev Infect Dis11:S519-S523, 1989 (suppl 3)
6.
Dressman GR, Kennedy RC: Anti-idiotypic antibodies: Implications of internal image-based vaccines for infectious diseases. J Infect Dis151:761-765, 1985
7.
Chapel H.: Essentials of ClinicalImmunology (ed 2). Chicago, IL, 1985 , p 151
8.
Hruby DE: Vaccinia virus vectors: New strategies for producing recombinant vaccines . Clin Microbiol Rev3:153-170,1990
9.
Gottlieb MS, Schroff R., Schanker HM, et al: Pneumocystitis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men. N Engl J Med305:1425-1431,1981
10.
Masur H., Michelis MA, Greene JB, et al: An outbreak of community-acquired Pneumocystitis carinii pneumonias . N Engl J Med305:1431-1438,1981
11.
Barre-Sinoussi G., Chermann JC, Rey F., et al: Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immunodeficiency syndrome. Science220:868-871, 1983
12.
Gallo RC, Wong-Staal F.: A human T-lymphotropic retrovirus (HTLV III) as the cause of the acquired immunodeficiency syndrome. Ann Intern Med103:679-689, 1985
13.
May RM, Anderson RM: Transmission dynamics of HIV infection. Nature326:137-142,1987
14.
Lucie PA, Chong-Mayer C., Levy JA: Mutational analysis of the human immunodeficiency virus: The orf-b region down-regulation virus replication. Proc Natl Acad Sci USA84:1434-1438,1987
15.
Muesing MA, Smith DH, Capon DJ: Regulation of mRNA accumulation by a human immunodeficiency virus transactivation protein. Cell48:691-701, 1986
16.
Verones FD, Copeland TD, Devico AI, et al: Characterization of highly immunogenic p66/p51 as reverse transcriptase of HTLV III/LAV. Science231:1298-1291, 1986
17.
McDougal JS , Kennedy MS, Slight JM, et al: Binding of HTLV-III/LAV to T4+ T-cells by a complex of the 110K viral protein and the T4 molecule . Science231:382-385, 1986
18.
Lifson JD, Reyes GR, McGrathe MS, et al: AIDS retrovirus induced cytopathology: Giant cell formation and involvement of CD4 antigen. Science232:1123-1127, 1986
19.
Perry VH, Gordon S.: Modulation of CD4 antigen on macrophages and microglial cells in rat brain . J Exp Med166:1138-1143,1987
20.
Dalgleish AG , Beverley Pcl, Clapham PR, et al: The CD4 antigen is essential component of the receptor for the AIDS retrovirus. Nature312:763-767, 1984
21.
Broder S., Mitsuya H., Yorchoan R., et al: Life cycle of human immunodeficiency virus. Ann Intern Med113:604-618, 1991
22.
Wong-Staal F., Hahn BH, Salahuddin SZ, et al: Genomic diversity of human T-lymphotropic virus type III. Science229:759-762, 1985
23.
Wiley RL, Rutledge RA, Dias S., et al: Identification of conserved and divergent domains within the envelope gene ofHIV. Proc Natl Acad Sci USA83:5038-5042, 1986 22. Saag MS, Hahn BH, Gibbons J., et al: Extensive variation of HIV-1 in vivo. Nature334:440-444, 1988
24.
Benn S., Rutledge R., Folks T., et al: Genomic heterogeneity of AIDS retroviral isolates form North America and Zaire. Science230:949-951, 1985
25.
Hahn BH, Shaw GM, Arya SK, et al: Genetic variation in HTLV-III/LAV over time in patients with AIDS or at risk for AIDS. Science232:1548-1553, 1986
26.
Koff WC, Hoth DF: Development and testing of AIDS vaccines. Science241:426, 1988
27.
Matthews TJ , Bolognesi DP: AIDS vaccines. Scientific American259:120-127,1988
28.
Fauci AS, Gallo RC, Koenig S., et al: Development and evaluation of a vaccine for human immunodeficiency virus (HIV) infection. Ann Intern Med110:373-385, 1989
29.
Altman A., Dixon FJ: Immunomodifiers in vaccines. Adv Vet Sci Comp Med33:301-343,1989
30.
Dolin R., Graham BS, Greenberg SB, et al: The safety and immunogenicity of a human immunodeficiency virus type I (HIV-1) recombinant gp160 candidate vaccine in humans. Ann Intern Med114:119-127, 1991
31.
Arthur LO, Pyle SW, Nara PL, et al: Serological responses in chimpanzees inoculated with human immunodeficiency virus glycoprotein (gp120) subunit vaccine. Proc Natl Acad Sci USA84:8583-8587,1984
32.
Lasky LA, Groopman JE, Fenni CW, et al: Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein. Science233:209-212, 1986
33.
Dalgeish AG , Thomson BJ, Chan TC, et al: Neutralization of HIV isolates by anti-idiotypic antibodies which mimic the T4 epitope: A potential AIDS vaccine . Lancet2:1047-1050, 1987
34.
Hu SL, Kosowski, Dalrympl JM: Expression of AIDS virus envelope gene in recombinant vaccinia viruses. Nature320:537-540,1986
35.
Chakrabrati S., Robert-Guroff M., Wong-Staal F., et al: Expression of the HTLV-III envelope gene by a recombinant vaccinia virus. Nature320:535-537, 1986
36.
Zarling JM, Morton W., Moran PA, et al: T-cell response to human AIDS virus in macaques immunized with recombinant vaccinia virus. Nature323:344-346, 1986
37.
Zagury D., Leonard R., Fouchard M., et al: Immunization against AIDS in humans. Nature326:249-250, 1987
38.
Berzofsky J. , Bensussan A., Cease K., et al: Antigenic peptide recognized by T-lymphocytes from AIDS viral envelop immune humans. Nature334:706-708, 1988
39.
Ho M.: Cytomegalovirus: Biology and Infection.New York, NY, Plenum, 1986, pp 280-330
40.
Prince AM, Szmuness W., Millian SJ, et al: A serologic study of cytomegalovirus infections associated with blood transfusions. N Engl J Med284:1125-1131, 1971
41.
Lang D., Scolnick EM, Willerson JT: Association of cytomegalovirus infection with the syndrome. N Engl J Med278:1147-1149, 1968
42.
Buhles WC, Mastre BJ, Tinker AJ, et al: Review of the treatment of 314 cases of life threatening or sight threatening cytomegalovirus infections. Rev Infect Dis10: S495-506, 1988 (suppl 3)
43.
Shepp DH, Dandiker PS, de Miranda P., et al: Activity of 9-[2-hydroxy-1-(hydroxymethyl)ethoxy methyl] guanine in the treatment of cytomegalovirus pneumonia. Ann Intern Med103:368-373, 1985
44.
Reed EC, Dandliker PS, Meyers JD: Treatment of cytomegalovirus pneumonia with 9-[2-hydroxy-1-(hydroxymethyl)ethoxy methyl] guanine and high dose corticosteroids. Ann Intern Med105:214-215, 1986
45.
Winston D., Pollard RB, Ho WG, et al: Cytomegalovirus immune plasma in bone marrow transplant recipients . Ann Intern Med97:11-18,1982
46.
Winston D., Gale RP, Meyer DV, et al: Infectious complications of human bone marrow transplantation . Medicine(Baltimore) 58:1-31, 1979
47.
Meyers J., Leszczynski J., Zaia JA, et al: Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation. Ann Intern Med82:442-446,1983
48.
Cottier H., Hassig A.: Immunodeficiency and ineffective immune responses, in Morel A, Nydegger UE (eds): Clinical Use of Intravenous Immunoglobulins. New York, NY, Academic, 1986, pp 1-11
49.
Condie RM, O'Reilly R.: Prevention of cytomegalovirus infection by prophylaxis with an intravenous, hyperimmune, native, unmodified cytomegalovirus globulin. Am J Med76:134-145, 1984
50.
O'Reilly RJ , Reich L., Gold J., et al: A randomized trial of intravenous hyperimmune globulin for the prevention of cytomegalovirus (CMV) infections following marrow transplantation: Preliminary results. Transplant Proc15: 1405-1411,1983
51.
Bowden RA, Sayers M., Flournoy N., et al: Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation . N Engl J Med314:1006-1010,1986
52.
Emmanuel D. , Cunningham I., Jules-Elysee K., et al: Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med109:777-782, 1988
53.
Reed EC, Bowden RA, Dandliker PS, et al: Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants . Ann Intern Med109:783-788, 1988
54.
Schmidt GM , Horak DA, Niland JC, et al: A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. N Engl J Med324:1005-1011, 1991
55.
Metcalf D.: The molecular control of cell division, differentiation, commitment and maturation in haemopoietic cells. Nature339:27-30, 1989
56.
Metcalf D.: The granulocyte-macrophage colony stimulating factors. Cell43:5-6, 1985
Gasson JC, Chen Isy, Westbrook CA: Lymphokines and Hematopoiesis. Normal and Neoplastic Hematopoiesis . New York, NY, Liss, 1983, pp 129-139
65.
Cebon J., Dempsey P., Fox R., et al: Pharmacokinetics of hGM-CSF using a sensitive immunoassay. Blood72:1340-1347,1988
66.
Lieschle GJ , Maher D., Cebon J., et al: Effects of bacterially synthesized recombinant human granulocyte-macrophage colony stimulating factor in patients with advanced malignancy. Ann Intern Med110:357-364, 1989
67.
Morstyn G., Campbell L., Souza LM, et al: Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet1:667-672, 1988
68.
Grabilove JL , Jakubowski A., Fain K., et al: Phase I study of granulocyte colony stimulating factor in patients with transitional cell carcinoma of the urothelium . J Clin Invest82:1454-1461, 1988
69.
Donahue RE, Johnson MM, Zon LI, et al: In vitro suppression of hematopoiesis after human immunodeficiency virus infection. Nature326:200, 1987
70.
Spivak JL, Bender BS, Quinn TC: Hematologic abnormalities in the acquired immune deficiency syndrome . Am J Med77:224-228,1984
71.
Zon LI, Arkin C., Groopman JE: Haematological manifestations of the human immunodeficiency virus . Br J Haematol66:251, 1987
72.
Stella CC, Ganser A., Hoelzer D.: Defective in vitro growth of hemopoietic progenitor cells in the acquired immunodeficiency syndrome. J Clin Invest80:2867, 1987
73.
Baldwin GC, Fuller ND, Roberts RL, et al: Granulocyte- and granulocyte-macrophage colony-stimulating factors enhance neutrophil cytotoxicity toward HIV-infected cells. Blood74:1673-1677, 1989
74.
Groopman JE , Mitsuyasu RT, DeLeo MJ, et al: Effect of recombinant granulocyte-macrophage colony stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome. N Engl J Med317:593-598, 1987
75.
Baldwin GC, Gasson JC, Quan SG, et al: Granulocyte-macrophage colony stimulating factor enhances neutrophil function in acquired immunodeficiency syndrome patients. Proc Natl Acad Sci USA85:2763-2766,1988
76.
Koynagi Y., O'Brien W., Zhao JQ, et al: Cytokines after production of HIV-1 from primary mononucleated phagocytes. Science241:1673-1675, 1988
77.
Buhles WC, Mastre BJ, Tinker AJ, et al: Ganciclovir treatment of life- or sight-threatening cytomegalovirus infection: Experience in 314 immunocompromised patients. Rev Infect Dis10:S495-S506,1988 (suppl 3)
78.
Pepose JS, Newman C., Bach MC, et al: Pathologic features if cytomegalovirus retinopathy after treatment with the antiviral agents ganciclovir. Opthalamology94:414-424, 1987
79.
Mitsuyasu RT , DeLeo MJ, Miles S., et al: Chronic dose subcutaneous administration of recombinant GM-CSF in patients with HIV-related leukopenia. IV International Congress on AIDS, Stockholm, Sweden, June 12-16, 1988 (abstr)
80.
Bhalla K., Birkhofer M., Grant S., et al: The effect of recombinant human granulocyte-macrophage colony-stimulating factor(rGM-CSF) on 3'-azido-3'-deoxythymidine (AZT)-mediated biochemical and cytotoxic effects on normal human myeloid progenitor cell. Exp Hematol17:17, 1989
81.
Perno CF, Yarchoan R., Cooney DA, et al: Replication of human immunodeficiency virus in monocytes. J Exp Med169:933-951, 1989
82.
Hammer SM, Gillis JM: Synergistic activity of granulocyte-macrophage colony stimulating factor and 3'-azido-3'deoxythymidine against human immunodeficiency virus in vitro. Antimicrob Agents Chemother31:1046-1050, 1987 80. Grossberg HS, Bonnem EM: GM-CSF with ganciclovir for the treatment of CMV retinitis in AIDS. N Engl J Med320:1560,1989
83.
Weisbart RH , Gasson JC, Golde DW: Colony stimulating factors and host defense . Ann Intern Med110:297-303, 1989
84.
Miles SA, Mitsuyasu RT, Lee K., et al: Recombinant human granulocyte colony stimulating factor increase circulating burst forming units-erythron and red blood cell production in patients with severe human immunodeficiency virus infection. Blood75:2137-2142, 1990
85.
Miles SA, Glaspy J., Chung Y., et al: Recombinant granulocyte colony stimulating factor increases neutrophils number and function but does not alter HIV expression in patients with AIDS. V International Conference on AIDS, Toronto, Ontario, Canada, June 4-9,1989 (abstr 558)
86.
Pruitt BA, McManus A.: Opportunistic infections in severely burned patients. Am J Med146-154, 1984
87.
Munster AM, Hoagland HC, Pruitt BA: The effect of thermal injury of serum immunoglobulins. Ann Surg170:965-969, 1970
88.
Bjornson AB , Altemeier WA, Bjornson S.: Changes in humoral components of host defense following burn trauma. Ann Surg186:88-96, 1977
89.
Eurenius K. , Brouse RO: Granulocytes kinetics after thermal injury . Am J Clin Pathol60:337-342, 1973
90.
Leguit P., Meinesz A., Zeijkemaker WP, et al: Immunological studies in burn patients. I. Lymphocytes transformation in vitro. Int Arch Allergy Appl Immunol44:101-121, 1973
91.
Miller CL, Baker CC: Changes in lymphocyte activity after thermal injury: the role of suppressor cells. J Clin Invest63:202-210,1979
92.
Warden GD, Mason AD, Pruitt BA: Evaluation of leukocyte chemotaxis in vitro in thermally injured patients . J Clin Invest54:1001-1004,1974
93.
Solomkin JS , Nelson RD, Chenoweth DE, et al: Regulation of neutrophil migratory function in burn injury by complement activation products . Ann Surg200:742-746, 1984
94.
Grogan JB: Altered neutrophil phagocytic function in burn patients. J Trauma16:734-738, 1976
95.
Alexander JW , Wixson DP: Neutrophil dysfunction and sepsis in burn injury. Surg Gynecol Obstet130:431-438, 1970
96.
Peterson VM , Hansbrough JF, Buerk C., et al: Regulation of granulopoiesis following severe thermal injury. J Trauma23:19-24, 1983
97.
Peterson VM , Robinson WA, Wallener SF, et al: Granulocyte stem cells are decreased in humans with fatal burns. J Trauma25:413-418, 1985
98.
Iyengar R., Peterson VM, Rundus C., et al: Postburn serum inhibits in vitro production of colony stimulating factor by mononuclear peripheral blood cells. Int J Cell Cloning4:472-482,1986
99.
Peterson VM , Ambruso DR, Emmett M., et al: Inhibition of colony-stimulating factor(CSF) production by postburn serum negative feedback inhibition mediated by lactoferrin . J Trauma11: 1533-1540, 1988
100.
Mooney DP, Gamelli RL, O'Reilly M., et al: Recombinant human granulocyte colony stimulating factor and Pseudomonas burn wound sepsis. Arch Surg123:1353-1357, 1988
101.
Silver GM, Gamelli RL, O'Reilly M.: The beneficial effect of granulocyte colony stimulating factor (G-CSF) in combination with gentamicin on survival after Pseudomonas burn wound infection . Surgery106:455-456, 1989
102.
Pizzo PA: Combating infectious in neutropenic patients. Hosp Pract93-110, 1989
103.
Bodey GP, Buckley M., Sathe YS, et al: Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med64:328-336,1965
104.
Young LS: Overview of infections in bone marrow transplantation recipients. Clin Haematol13:661-678, 1984103. Winston DJ, Winston GH, Howel A., et al: Cytomegalovirus infections associated with leukocytes transfusion. Ann Intern Med93:671-675, 1980
105.
Winston DJ , Ho WG, Gale: Therapeutic granulocyte transfusion for documented infections. Ann Intern Med197:509, 1982
106.
Hiemenz JW, Pizzo PA: New developments in the etiology, diagnosis, treatment and preventions of infectious complications in patients with leukaemia, in Bloomfield CD (ed): Chronic and acute leukemias in adults. Boston, MA,Nijhoff, 1985, pp 283-297
107.
Young LS: The role of granulocyte transfusions in treating and preventing infection . Cancer Treat Rep67:109, 1983
108.
Frei E. III, Canellos GP: Dose: Critical factor in cancer chemotherapy. Am J Med69:585-594, 1980
109.
Bonnem EM, Morstyn G.: Granulocyte-macrophage colony stimulating factor (GM-CSF) current status and future development. Sem Oncol15:46-51, 1988
110.
Canellos GP : The case for high dose chemotherapy: Is chemotherapy's last gamble? EurJ Clin Oncol23:351-355, 1987
111.
Dower D., Dagi O., Shaked N., et al: Response to recombinant murine GM-CSF in melphalan treated mice . Blood70:389, 1987 (suppl 1)
112.
Welte K., Bonilla MA, Billio AP, et al: Recombinant human granulocyte colony stimulating factor: Effects on hematopoiesis in normal and cyclophosphamide-treated primates. J Exp Med165:941-948, 1987
113.
Mayer P., Lam C., Obenaus E., et al: Recombinant human GM-CSF induces leukocytosis and activates peripheral blood polymorphonucleated cells in non-human primates. Blood70:206-213,1987
114.
Antman K., Griffin W., Elias A., et al: Effect of recombinant granulocyte-macrophage colony stimulating factor on the chemotherapy induced myelosuppression. N Engl J Med319:593-598, 1988
115.
Antman K., Griffin E., Elias A.: Effect of recombinant granulocyte-macrophage colony stimulating factor on the chemotherapy induced myelosuppression in sarcoma patients. Proc Am Soc Clin Oncol7:160, 1988 (abstr)
116.
Socinski MA , Cannistra SA, Elias A., et al: Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet1:1194-1198, 1988
117.
Grabilove JL, Jakubowski A., Scher H., et al: Effects of granulocyte CSF on neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the urothelial. N Engl J Med318:1414-1422, 1988
118.
Bronchud MH , Scarff JH, Thatcher N., et al: Phase I/II study of recombinant human granulocyte granulocyte colony stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. BJ Cancer56:809-813, 1987
119.
Nishimura H., Kwakita M., Takatsuki K.: Effect of G-CSF on leukopenia due to chemotherapy for lymphoid malignancy. Exp Hematol17:519,1989
120.
Morstyn G. , Souza LM, Keech J., et al: Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy . Lancet1:667-672, 1988
